Newron extends Senior Management team and strengthens commitment to ESG

Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology

Newron announces AGM 2022 results

Newron announces 2021 financial results and provides outlook for 2022

Change in Newron Board of Directors

Newron receives fifth tranche from financing agreement with European Investment Bank (EIB)

Newron announces Half-Year 2021 results

Newron receives fourth tranche from financing agreement with European Investment Bank (EIB)

Newron initiates first potentially pivotal study with evenamide in patients with schizophrenia

Newron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USA

Pagination